Hepatitis A

Hepatitis A

Vaccination Offers Long-Term Immunity

The Hepatitis A Virus

The HAV Replication Cycle

Hepatitis A

– Transmission is typically by the faecal-oral route:• Contamination of food or water• Close person-to-person contact• Sexual oral-anal contact

Less typically, hepatitis A may be transmitted in body fluids such as blood and saliva .

Symptomatic Ratio in Day - Care Children

“ Clinical illness is rare in children infected in the first year of life , occurs in about one - fourth of

those under the age of 15, and is almost universal in adults .

Gust &Feinstone

1990

Symptoms of Hepatitis A in Children & Adults

Complications of Hepatitis A

• Cholestatic Joundice

• Relapsing Hepatitis

• Fulminant Hepatitis

Hepatitis A: Clinical Characteristics of Patients by Age Group

Clinical Characteristics <1-14yrs 15-39yrs 40+yrs (n=1692) (n=4918) (n=1386)

Jaundice 81.7% 86.8% 70.3%

Hospitalised for Hepatitis 17.1% 32.2% 70.3%

Death as a result of Hepatitis 0.1% 0.3% 2.1%

“As there is no specific treatment for hepatitis A, management is basically Supportive…”

Dr lan D Gust & Dr Sptephen M Feinstone

Highly developed countries , such as japan , Australia , and most parts of North America and Europe , are largely low endemicity regions for hepatitis A

Many residents of these areas have no natyral immunity against hepatitis A virus

Morbidity & Mortality per 100,000 Unprotected Travellers to Developing Countries per Month of

Stay Abroad INFECTION Morbidity Case Fatality rate(%)

Mortality_____________________________________________________________________

_

Malaria,West Africa 2400 2(for p. falciparum) 40Malaria ,South America 50 2(for p. falciparum) 0.15Hepatitis A: generally 300(-600) 0.1 0.3(-0.6) Hepatitis A:backpackers 2000 0.1 2Hepatitis B:expatriates 80(-240) 2 1.6(-4.8)Typhoid fever : usual destination 3 1 0.03Typhoid : India , N-,W-Africa 30 1 0.3Ppliomyelitis : symptomatic 0.1 20 0.02Poliomyelitis: Symptomatic 0.1 20 0.02Poliomyelitis: asymptomatic2(-100) - (contacts)Cholera 0.3 2 0.006

Travellers at Risk of HAV Infection

• Tourists

• Business travellers

• Foreign aid workers

• Airline Personnel

• Missionaries

• Professionals working abroad

“Symptomatic hepatitis A is the most frequently occurring immunisable infection in travellers”

“The incidence rate of symptomatic hepatitis A for a one month journey from an industrialised country to a developing country is 3/1000 for the usual non-immune traveller”

“This applies also to tourists staying in renowned hotels”

Uk Travellers Abroad

Protection is advised for non-immune

Travellers from the UK visiting all countries

Outside of Northern Europe, North America,

New Zealand and Australia

“ In unprotected travellers , hepatitis A occurs 40 times more frequently than typhoid fever and 800 times more frequently than cholera”

Steffen 1991

This availabillity of an effective hepatitis A vaccine will make it possible , at last, to provide protection against one of the oldest disease threats to the healthy soldier

Col WH Bancroft MDWalter Reed Army Institute,washington DC

This enhanced risk of hepatitis Ainfection for the nursing profession … prompts us to demand that (this type of disease) should also of professional diseases

Windorfer et al 1989

Hepatitis A in both employees and household contacts is strongly related to contact with children whoo attend day-care centre

Hadler et al

1980

Protection is advised for close contacts of all ages in order to control outbreaks of hepatitis A in households and in institutions

Joint Committee on

Vaccination and Immunisation

Prevention of Hepatitis A

• Improvement in water Supply, sanitation and hygiene

• Isolation of infected individuals

• Passive immunisation (IG)

• Active immunisation ( vaccination)

Passive Immunisation

• Short –term protection- requires frequent renewal

• No stimulation of antibody production in recipient

• Plasma- derived product

• Large injection volumes

Active Vaccination • Long –term immunity from active

vaccination

• Stimulates antibody production in the recipient

• Non plasma-derived product

• Small IM injection volumes administered via deltoid

Recombinant Vaccines

• HAV epitope is complex

• Current technology has not been able to reproduce the epitope in isolation

• The development of a recombinant vaccine against hepatitis A will be very difficult

Live, Attenuated Vaccines

• Difficult to develop

• Under-attenuation may lead to active infection

• Over-attenuation may lead to vaccine failure

• Re-emergence infection in both recipient and close contacts

Inactivated Vaccine

• Killed virus – incapable of causing active infection

• Killed Virus – possesses the antigens which stimulate the production of

anti-HAV

• Can be developed using proven technology (polio, salk)

‘Havrix’ Hepatitis A Vaccine Seroconversion Rates

Injections given at months o ad 1 with a booster dose at 6 months

Blood Sample Taken

M O N T H

1 2 7

% Seroconversion 95.6 99.9 100

(987/1032) (1035/1036) (592/592)

Hepatitis A

Vaccination Offers Long- Term Immunity

Havrix

Hepatitis A VaccinePrescribing Information and References available at this

meeting

SBSmithkline Beecham

Pharmaceuticals

‘Havrix’ is a trade mark1992 smithkline Beecham Pharmaceuticals